Korea S.E.
06:00:00 2024-04-23 pm EDT
5-day change
1st Jan Change
208,000
KRW
+0.97%
+4.37%
+39.22%
Hugel, Inc.'s Equity Buyback Plan Extended till March 10, 2022.
On September 9, 2021, the company announced that it has extended its plan duration till March 10, 2022.
Hugel, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares.
Mar. 27
CI
Hugel, Inc. authorizes a Buyback Plan.
Mar. 26
CI
Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on November 13, 2023.
Feb. 15
CI
Hugel, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares.
Feb. 13
CI
Hugel, Inc. authorizes a Buyback Plan.
Feb. 12
CI
Hugel to Retire 54.6 Billion Won Treasury Shares
Dec. 28
MT
Hugel, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares.
Nov. 13
CI
Hugel, Inc. authorizes a Buyback Plan.
Nov. 12
CI
Hugel Resubmits BLA for Its Botulinum Toxin, Letybo to the U.S. Fda
23-09-01
CI
Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on February 14, 2023.
23-08-17
CI
Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on February 14, 2023.
23-08-17
CI
Hugel, Inc.'s Equity Buyback announced on February 14, 2023, has expired with 400,000 shares, representing 3.45% for KRW 48,413.36 million.
23-08-13
CI
Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on February 14, 2023.
23-05-19
CI
Hugel, Inc. acquired additional 3.13% stake in Across Co., Ltd for KRW 9.385 billion.
23-05-03
CI
Hugel America, Inc. announced that it has received KRW 50.1075861 billion in funding from Hugel, Inc.
23-04-29
CI
Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on April 7, 2022.
23-04-06
CI
Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on April 7, 2022.
23-04-06
CI
Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on April 7, 2022.
23-04-06
CI
Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on April 7, 2022.
23-04-06
CI
Hugel, Inc.'s Equity Buyback announced on April 7, 2022, has expired with 379,114 shares, representing 3.18% for KRW 49,977.35 million.
23-04-05
CI
Hugel Announces Board Appointments
23-03-31
CI
Hugel, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-22
CI
Hugel America, Inc. announced that it expects to receive KRW 50.1075861 billion in funding from Hugel, Inc.
23-03-08
CI
Hugel, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares.
23-02-14
CI
Hugel, Inc. authorizes a Buyback Plan.
23-02-13
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Hugel Inc is a Korea-based company mainly engaged in the manufacture of biopharmaceuticals. The Company's product portfolio consists of botulinum toxins which used for treatment of benign essential blepharospasm and temporary improvement of moderate to severe glabellar lines including 50 unit types, 100 unit types and 200unit types; hyaluronic acid (HA) fillers which used for temporary removal of facial wrinkles including the chaeum premium No.1, the chaeum premium No.2, the chaeum premium No.3m the chaeum premium No.4, the chaeum MID 20A, the chaeum DEEP 20A, the chaeum SUB-Q 20A and the chaeum VOLUS 20A; wellages, blue roses and other cosmetics. The Company sells its products in domestic and overseas markets.
More about the company
Last Close Price
208,000
KRW
Average target price
218,778
KRW
Spread / Average Target
+5.18%
Consensus
1st Jan change
Capi.
+39.22% 1.64B -2.86% 87.37B +3.95% 41.01B -21.94% 28.08B +53.11% 24.72B -5.41% 17.47B -44.23% 11.69B -17.60% 11.6B -13.96% 11.56B -0.22% 8.44B
Biopharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
HUGEL, INC. 
